Berry-Kravis, Elizabeth M.
Lindemann, Lothar
Jønch, Aia E.
Apostol, George
Bear, Mark F.
Carpenter, Randall L.
Crawley, Jacqueline N.
Curie, Aurore
Des Portes, Vincent
Hossain, Farah
Gasparini, Fabrizio
Gomez-Mancilla, Baltazar
Hessl, David
Loth, Eva
Scharf, Sebastian H.
Wang, Paul P.
Von Raison, Florian
Hagerman, Randi
Spooren, Will
Jacquemont, Sébastien
Article History
First Online: 8 December 2017
Competing interests
: E.B.K. has received funding from Novartis, Roche, Alcobra, Neuren, Cydan, Fulcrum, GW, Marinus, Edison and Neurotrope Pharmaceuticals to consult on trial design and development strategies and/or conduct clinical trials in fragile X syndrome (FXS), Vtesse to run clinical trials in Niemann–Pick type C, and from Asuragen Inc. to develop testing standards for FMR1 testing. L.L. is a full-time employee of F. Hoffmann-La Roche AG, he owns stock and stock options in F. Hoffmann-La Roche AG, and he is a co-inventor on patents originating in his work at F. Hoffmann-La Roche AG. A.E.J. participated in clinical trials led by Novartis Pharmaceuticals and has no further competing interests to declare. G.A. was a former full-time employee of Novartis Pharma and is currently an employee of Shire Pharmaceuticals. M.F.B. declares no competing interests. R.L.C. was a former full-time employee of Seaside Therapeutics and declares no further competing interests. J.N.C. declares no competing interests. A.C. participated in clinical trials led by Novartis Pharma and has no further competing interests to declare. V.D.P. participated in clinical trials led by Novartis Pharma and has no further competing interests to declare. F.H. is a former employee of Novartis Pharmaceutical Corporation and is currently employed by Celgene. F.G. is an employee and a shareholder of Novartis. B.G.M. is an employee of Novartis Institutes for Biomedical Research. D.H. has provided paid consultation regarding clinical trials in FXS to Novartis, Roche and Seaside Therapeutics. E.L. declares no competing interests. S.H.S. is a full-time employee of F. Hoffmann-La Roche AG. P.W. declares no competing interests. F.V.R. is a full-time employee and shareholder of Novartis Pharma. R.H. has received funding from Novartis, Roche/Genentech, Alcobra, Marinus and Neuren for clinical trials in FXS and has consulted with Roche/Genentech, Zynerba and Novartis regarding fragile X treatment and clinical trial design. W.S. is an employee of F. Hoffman-La Roche. S.J. has served on the Novartis Fragile X Advisory Board and has consulted for Novartis and WG Pharma.